Table 3.

Ascertainment (as %) during variant-dominant periods

Complementary SS	Comparison with ONS prevalence
	Delta	BA.1	BA.2
C19PRinH	0.48 (0.4, 0.6)	0.21 (0.2, 0.2)	0.19 (0.2, 0.2)
EDSS	0.04 (0.0, 0.0)	0.02 (0.0, 0.0)	0.01 (0.0, 0.0)
111calls	0.27 (0.2, 0.3)	0.09 (0.1, 0.1)	0.10 (0.1, 0.2)
111web	0.29 (0.3, 0.3)	0.06 (0.1, 0.1)	0.07 (0.1, 0.1)

	Comparison with ONS incidence
	Delta	BA.1	BA.2
P12	42.5 (37.0, 49.1)	30.4 (23.9, 38.1)	8.93 (7.0, 11.3)
HospAdm	0.87 (0.8, 1.1)	0.55 (0.4, 0.6)	0.48 (0.4, 0.7)
ZOE	75.6 (67.6, 84.8)	53.1 (43.7, 66.4)	68.6 (54.4, 110.5)
EDSS	0.42 (0.4, 0.5)	0.16 (0.1, 0.2)	0.11 (0.1, 0.1)
111calls	3.15 (2.8, 3.6)	0.86 (0.7, 1.1)	1.00 (0.6, 1.7)
111web	3.35 (2.8, 3.8)	0.64 (0.5, 0.8)	0.74 (0.4, 1.2)

	Comparison with P12 incidence
	Delta	BA.1	BA.2
HospAdm	2.13 (1.9, 2.5)	1.83 (1.2, 2.3)	7.06 (3.5, 8.8)
ZOE	176.4 (154, 207)	162.9 (121, 277)	949.4 (451, 1411)
EDSS	1.03 (0.9, 1.3)	0.52 (0.5, 0.6)	1.40 (0.8, 1.8)
111calls	6.90 (6.1, 9.1)	2.80 (2.2, 4.1)	12.02 (5.4, 22.2)
111web	7.72 (6.1, 9.1)	2.08 (1.6, 2.8)	8.79 (3.9, 16.8)

Notes: Values are for entire monitoring period, ascertainment percentage median (IQR). Tests for between group differences (in rows) using Welch’s one-way ANOVA were all significant at p < < 0.001